Clarissa Parker to Adult
This is a "connection" page, showing publications Clarissa Parker has written about Adult.
Connection Strength
0.141
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
Score: 0.023
-
A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15.
Score: 0.012
-
Genome-wide Associations Reveal Human-Mouse Genetic Convergence and Modifiers of Myogenesis, CPNE1 and STC2. Am J Hum Genet. 2019 12 05; 105(6):1222-1236.
Score: 0.012
-
An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep; 5(8):381-7.
Score: 0.010
-
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704.
Score: 0.009
-
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7.
Score: 0.009
-
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25.
Score: 0.009
-
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Mar; 47(3):413-9.
Score: 0.008
-
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb; 47(2):253-9.
Score: 0.008
-
Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004 Oct; 11(10):900-6.
Score: 0.008
-
Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res. 2012 Jul; 46(7):882-9.
Score: 0.007
-
Brain metastases. Curr Treat Options Oncol. 2001 Dec; 2(6):537-47.
Score: 0.007
-
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53.
Score: 0.006
-
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60.
Score: 0.004
-
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2006 Jan; 17(1):104-9.
Score: 0.004
-
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug 15; 98(4):779-88.
Score: 0.004